![](/img/cover-not-exists.png)
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration resistant prostate cancer
Grubmüller, B., Senn, D., Kramer, G., Baltzer, P., D’Andrea, D., Eidherr, H., Haug, A., Wadsak, W., Pfaff, S., Hacker, M., Shariat, S.F., Hartenbach, M.Volume:
18
Journal:
European Urology Supplements
DOI:
10.1016/S1569-9056(19)30513-5
Date:
March, 2019
File:
PDF, 87 KB
2019